BUZZ-U.S. Stocks on the Move-USEC, Vivus, Marchex, Emcore (Thomson Reuters)
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s
** APPLE INC, $101.929, +0.34 pct
The company's iPhone 6 received regulatory approval in China for use on domestic frequencies, but still requires one more critical license before it may be sold in the country, the official Xinhua news agency reported on Thursday.
Separately, Internet news website Daily Dot reported, citing sources, that Apple is set to launch two new iPads and release the next version of its Mac operating system at its next event on Oct. 21. Apple plans to unveil the sixth generation of its iPad and the third edition of the iPad mini, as well as its operating system OS X Yosemite, which has undergone a complete visual overhaul, the website said.
** MSCI INC, $49.07, +6.01 pct
The stock market indexes provider declared its first-ever quarterly dividend and more than doubled its stock repurchase program to $850 million from $300 million. The company said the buyback, which includes a $300 million accelerated share repurchase agreement with Goldman Sachs, and the dividend would return about $1 billion to shareholders by the end of 2016.
** MARCHEX INC, $4.185, -44.20 pct
The mobile advertising company cut its call-driven revenue forecast for fiscal 2014, hurt by a revision of fee model by its customer Allstate Corp, for the fourth quarter ending December. Marchex said that going forward, Allstate has decided to adopt fixed fee model instead of the current performance-based model. Marchex said it "does not believe it is in its best long-term interest to work under such an arrangement."
** REPROS THERAPEUTICS, $9.58, -25.62 pct
** LIPOCINE INC, $5.763, -23.16 pct
A U.S. Food and Drug Administration advisory panel voted to restrict the use of testosterone replacement therapies to people with medically related low testosterone, such as a genetic disorder or a tumor. If implemented, the restriction would prevent companies from marketing products for age-related low testosterone.
Repros and Lipocine's lead drugs are being tested to treat low testosterone levels.
** USEC INC, $1.97, -22.75 pct
The Uranium supplier said it expected to emerge from Chapter 11 restructuring on Sept. 30 under the name Centrus Energy Corp .
Equity holders will be left with about 5 percent of new shares, according to a reorganization plan confirmed by a bankruptcy court in Delaware.
USEC filed for bankruptcy in March, after struggling with weak prices for the enriched uranium it supplies to nuclear power plants.
** FOAMIX PHARMACEUTICALS LTD, $7.15, +19.17 pct
Shares of the pharmaceutical company soared as much as 83 percent to $11 in their debut, valuing the company at about $218.8 million. The offering of 6.7 million shares raised about $40.2 million.
** PROQR PHARMACEUTICALS BV, $17.1, +31.54 pct
The company's shares rose as much as 68 percent to $21.87 on their debut, valuing the company at about $458.5 million. The offering, which was priced at $13 per share, raised about $97.5 million.
** VIVUS INC, $4.7899, +23.45 pct
** AUXILIUM PHARMACEUTICALS, $31.04, -0.45 pct
The U.S. Food and Drug Administration approved a faster-acting version of Vivus' erectile dysfunction drug, Stendra. The drug, which was first approved in 2012, is sold by in the United States and Canada by Auxilium.
** SINOCOKING COAL & COKE CHEMICAL INDUSTRIES INC, $4.63, -24.35 pct
The coal processor and two other investors agreed to sell 2.8 million shares in an offering. The company said it expected aggregate gross proceeds from the sale of shares to be about $14.3 million. (http://1.usa.gov/1rf2MjU)
** SONY CORP, $17.91, -5.14 pct
The Japanese consumer electronics maker's U.S.-listed shares are on track for their worst week since November 2013. The company cut on Wednesday its profit forecast for the sixth time on CEO Kazuo Hirai's watch.
** EMCORE CORP, $5.49, +27.97 pct
The semiconductor-based products provider agreed to sell its space solar power business to an affiliate of private equity firm Veritas Capital for $150 million in cash.
Emcore said separately that its CEO, Hong Hou, had resigned in connection with the sale.
** PENN WEST PETROLEUM LTD, $7.61, +8.56 pct
The Canadian oil producer reported a profit for the second quarter compared with a year-earlier loss. The company also said it was strengthening its accounting practices after a review uncovered irregularities that forced to company to restate some of its prior results.
** RITE AID CORP, $5.395, -18.75 pct
The third largest U.S. drugstore chain cut its full-year profit forecast for the second time this year as lower margins from its pharmacy business continue to eat into earnings.
** PIER 1 IMPORTS INC, $12.55, -19.24 pct
The home furnishings and decor products importer cut its full-year earnings forecast to $0.95-$1.05 per share from $1.14-$1.22. The company also reported a weaker-than-expected profit for the second quarter, hurt by a decline in merchandise margins and lower-than-expected sales. Pier 1 said investments in its omni-channel strategy, which integrates online sales within stores, were hurting its near-term financial performance.
** HERCULES OFFSHORE INC, $2.7199, -10.53 pct
Cowen and Co cut its price target on the company's stock to $4 from $6. The median price target on the stock is $4.50. "The drop-off in demand has been more pronounced than we anticipated, and activity is set to stay depressed through the end of the hurricane season," Cowen and Co analysts wrote in a note.
** A10 NETWORKS INC, $10.1, -9.50 pct
The 180-day lockup period for the network equipment maker stock has ended, Seeking Alpha reported. The lockup period began on March 20with the company's IPO. (http://bit.ly/1qhtDpU)
** CONAGRA FOODS INC, $33.12, +3.47 pct
The maker of Hunt's Ketchup and Chef's Boyardee pastas reported a higher quarterly net income as sales increased in its commercial foods business.
** FLEXION THERAPEUTICS, $17.99, -7.17 pct
The U.S. Food and Drug Administration placed a hold on patient enrollment and dosing on the company's ongoing mid-stage trial on an experimental drug, codenamed FX006 - Flexion. The drug was being studied as a potential treatment for patients with osteoarthritis of the knee. The FDA indicated the clinical hold was due to single occurrence of infection in the injected knee joint of a patient.
** PDL BIOPHARMA INC, $7.78, -8.25 pct
The company's auditor Ernst & Young LLP said it would resign effective Sept. 11. PDL said it was surprised by the resignation as it did not have any disagreements with the auditor.
** ERICSSON, $13.23, +4.59 pct
The world's top mobile network equipment market will stop developing modems, it said, shutting a loss-making unit it took on after joint venture partner STMicroelectronics pulled out a year ago.
** YAHOO INC, $41.9001, -1.62 pct
Chinese e-commerce giant Alibaba Group Holding Ltd , in which Yahoo owns 23 percent stake, is set to sell some $22 billion of shares on Thursday, capping a two-week road show that drew frenzied interest from investors worldwide and may be the world's largest ever initial public offering.
Yahoo's stock was the most traded share on the Nasdaq on Thursday.
** DISCOVERY COMMUNICATIONS INC, $39.99, +2.90 pct
** HASBRO INC, $53.81, +0.07 pct
Discovery is seeking a controlling interest in The Hub, reducing partner and toymaker Hasbro's share of the children's cable TV network, the Wall Street Journal reported on Wednesday, citing sources familiar with the matter.
** PEABODY ENERGY CORP, $13.32, -6.13 pct
** ARCH COAL INC, $2.64, -5.71 pct
** ALPHA NATURAL RESOURCES INC, $3.17, -6.21 pct
** WALTER ENERGY INC, $3.08, -10.47 pct
Goldman Sachs lowered its outlook for U.S. thermal coal prices in 2015 to reflect coal plant retirements, rail issues, lower exports and higher levels of coal-to-gas switching. The brokerage also cut its rating on Peabody Energy's shares to "sell" from "neutral" and cut its price target on the stock to $13 from $15. Analysts cited challenging prices and margins for thermal coal in the United States and for metallurgical coal in Australia as reason for rating and price target cuts.
** EPR PROPERTIES, $52.3, -4.27 pct
The real estate investment trust said it planned to sell 3.2 million common shares, but it did not disclose the share price. The company plans to use the proceeds from the offering to reduce debt and to fund acquisitions and real-estate projects.
** CONTINENTAL RESOURCES INC, $69.47, -8.38 pct
The company boosted its 2014 capital budget on Wednesday, citing more-expensive oil well completion techniques in North Dakota's Bakken shale and a new project in Oklahoma. The company now expects to spend $4.55 billion this year, up from a previous forecast of $4.05 billion.
** TRINA SOLAR LTD, $14.89, +2.90 pct
** RENESOLA LTD, $3.47, +2.66 pct
** JINKOSOLAR HOLDING CO LTD, $33.24, +0.73 pct
** YINGLI GREEN ENERGY HOLDING CO LTD, $3.685, +0.96 pct
Jeferries & Co reiterated its positive outlook on solar stocks. "(Photo voltaic) demand appears to be indeed recovering with module manufacturers ramping up production and pricing turning more favorable," analysts wrote in a note.
** AIR PRODUCTS AND CHEMICALS INC, $133.37, +1.87 pct
The industrial gas supplier said it would reorganize into seven reporting segments. The company's stock rose as much as 5 percent to a record high of $137.45. (Compiled by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)
Posts
